SlipstreamJobs tracks this role from the company's public career site. Apply directly on the employer's site.
Olema Oncology is a clinical-stage biopharmaceutical company focused on transforming the standard of care for breast cancer and beyond. The company is undergoing transformation into a fully integrated oncology company with top-line data from its lead program expected later in 2026 and a first potential commercial launch on the horizon in 2027.
The lead product candidate, palazestrant, is a novel oral complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. OPERA-01, the Phase 3 trial of palazestrant as monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), is expected to deliver top-line data in fall 2026, potentially leading to the first approval and commercial launch in 2027. OPERA-02, the Phase 3 trial combining palazestrant with ribociclib in frontline ER+/HER2- MBC patients, is actively enrolling. Palazestrant has the potential to access a $15 billion global market opportunity.
The follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with potential to generate further value and impact the metastatic breast cancer treatment landscape, particularly in combination with palazestrant. The company recently reported encouraging Phase 1 monotherapy data across multiple solid tumor types and is advancing patient enrollment in ongoing combination arms in MBC.
As the company transitions toward commercialization, this Director role will lead commercial insights and analytics efforts to support market strategy, competitive positioning, and commercial launch planning. The ideal candidate will have deep expertise in healthcare analytics, market research, and commercial strategy in oncology or similar therapeutic areas, with the ability to translate complex data into actionable business insights.
